PMN ProMIS Neurosciences Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1374339 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-32.5%
TTM EPS YoY62.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-152.3%
ROA-113.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets11.4%
Debt / equity0.00x
Current ratio8.83x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio7.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $6.71M | $9.52M | $6.97M | $9.37M | $9.80M | $8.75M | $5.46M | $4.32M |
| SG&A expense | $1.91M | $2.74M | $1.67M | $1.40M | $1.95M | $1.43M | $2.00M | $1.68M |
| Operating income | -$8.62M | -$12.27M | -$8.64M | -$10.77M | -$11.75M | -$10.18M | -$7.46M | -$6.00M |
| Net income | -$8.16M | -$11.73M | -$8.24M | -$10.67M | -$11.58M | -$10.12M | -$7.35M | -$238,207 |
| EPS (basic) | -0.89 | -1.28 | -1.26 | — | -5.93 | -7.26 | -5.27 | — |
| EPS (diluted) | -0.89 | -1.28 | -1.26 | — | -5.93 | -7.26 | -5.27 | — |
| Weighted avg. shares (diluted) | 9.14M | 9.14M | 6.53M | — | 1.95M | 1.39M | 1.39M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $44.07M | $53.43M | $63.81M | $6.12M | $15.40M | $4.51M | $8.36M | $13.29M |
| Short-term investments | $33,753 | $33,753 | $33,753 | $33,753 | $33,051 | $33,051 | $33,051 | $33,051 |
| Current assets | $47.16M | $56.69M | $65.61M | $9.18M | $21.46M | $9.51M | $13.65M | $18.91M |
| Total assets | $47.16M | $56.69M | $67.41M | $9.18M | $21.46M | $9.51M | $13.65M | $18.91M |
| Current liabilities | $5.34M | $7.22M | $6.61M | $10.41M | $12.21M | $9.82M | $4.06M | $2.22M |
| Total liabilities | $5.40M | $7.29M | $6.69M | $10.44M | $12.27M | $9.89M | $4.17M | $2.42M |
| Shareholders' equity | $41.76M | $49.40M | $60.72M | -$1.26M | $9.19M | -$382,579 | $9.47M | $16.49M |
| Shares outstanding | 8.97M | 8.97M | 8.97M | 2.15M | 53.81M | 32.69M | 32.69M | 1.31M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.38M | -$10.39M | -$12.38M | -$9.28M | -$10.06M | -$3.85M | -$4.93M | -$8.72M |
| Financing cash flow | $21,072 | $0 | $70.08M | -$1 | — | — | — | $469,999 |
| Stock-based compensation | $482,640 | $408,895 | $189,425 | $203,171 | $197,147 | $212,015 | $245,295 | $623,189 |
Free plan shows the latest 8 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.